Abaxis Announces the Launch of Kidney Profile Plus Panel
UNION CITY, Calif., Sept. 18, 2012 /PRNewswire/ — Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point of care instruments and consumables for the medical, research, and veterinary markets, and providing reference lab services to the veterinary and research markets, announced today the launch of the VetScan Kidney Profile Plus Rotor exclusively for use on the VetScan VS2 Chemistry instrument. The new KPP rotor contains all critical chemistry analytes needed to diagnose and monitor kidney disease in canine, feline, and equine species.
Acute and chronic renal disease is commonly seen in veterinary practices in both cats and dogs. The new Kidney Profile Plus panel offers veterinarians a complete and cost-effective solution to diagnose and monitor kidney disease in their patients, especially when used alongside other VetScan point of care instruments for hematology and blood gas analysis.
Dr. Craig Tockman, Director of Professional Services for Abaxis commented, “The comprehensive test configuration of the Abaxis VetScan Kidney Profile Plus provides the veterinarian with every important value to assess the health of the patient’s kidney function at a much lower cost than other panels or individual tests. This will allow better testing compliance on the part of the pet owner leading to better patient care.”
Martin Mulroy, Chief Commercial Officer at Abaxis, added, “The Kidney Profile Plus is the latest addition to an already extensive menu of Abaxis panels developed for the VetScan Chemistry Instrument. This new product offers the simplicity, cost-effectiveness, and the medically relevant results the veterinary community has come to expect from Abaxis.”
The VetScan VS2 instrument now performs 25 different tests configured in 10 unique panels. Almost one in three veterinary practices in North America incorporate Abaxis instruments into routine wellness testing and annual check-ups, as an aide in the diagnosis of sick pets, and in emergency and critical care cases.
Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer. The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections, Parvovirus, Giardia and Lyme disease. Abaxis, through its AVRL division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide.
This press release includes, statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Abaxis’ cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this press release or in Abaxis’ conference call may be affected by risks and uncertainties, including, but not limited to, those related to losses or system failures with respect to Abaxis’ facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis’ products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis’ intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Abaxis’ Annual Report on Form 10-K for the fiscal year ended March 31, 2012 and Abaxis’ other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500
SOURCE Abaxis, Inc.